Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review - Wikidata - wikimedia - TriplyDB

Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review

Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review

http://www.wikidata.org/entity/Q21198850

about

Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancer Infectious complications in head and neck cancer patients treated with cetuximab: propensity score and instrumental variable analysis Update on the role of imaging in management of metastatic colorectal cancer Efficacy and safety of target combined chemotherapy in advanced gastric cancer: a meta-analysis and system review The role of epidermal growth factor receptor mutations and epidermal growth factor receptor-tyrosine kinase inhibitors in the treatment of lung cancer.Safety profile of new anticancer drugs.Cetuximab in non-melanoma skin cancer.A rare but severe pulmonary side effect of cetuximab in two patients.Treatment related severe and fatal adverse events with cetuximab in colorectal cancer patients: a meta-analysis.Epidermal growth factor receptor and metastatic colorectal cancer: insights into target therapies Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses.

P2860

Q26830569-201D07AA-A3F7-4976-8C52-BB76405D987E Q34198721-ED142CD1-5540-47DD-A68A-3F20F23156F7 Q34499968-7584D2D6-5DF0-490A-81A6-11034E73A989 Q35285305-B18952A9-D561-44DD-8D28-7B5D83167C4F Q36134904-45332C94-D9A0-42C1-98A3-627EFD901E97 Q37132805-60E77D7A-B97F-4036-A1C5-A20650ACF5B9 Q37696502-E8FCA72B-67DB-4112-86BF-C9094C952501 Q38004033-7AF1FC94-F76D-45F5-A577-B82C041DD5F4 Q38030496-670F8DCD-53E0-47C4-A2BD-636644662FAC Q38115675-6ABD418A-5A90-4A0D-909C-FCCBD2983D8D Q42696006-C5F8C4FF-AFF1-415A-9D9D-E9F57052C544 Q42908395-4EFC94D1-3229-40AA-87B0-7ED35B54AA17

P2860

Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review

http://www.wikidata.org/entity/Q21198850

description

2009 nî lūn-bûn

@nan

2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Association of cetuximab with ...... tients: a comprehensive review

@ast

Association of cetuximab with ...... tients: a comprehensive review

@en

Association of cetuximab with ...... tients: a comprehensive review

@en-gb

Association of cetuximab with ...... tients: a comprehensive review

@nl

type

label

Association of cetuximab with ...... tients: a comprehensive review

@ast

Association of cetuximab with ...... tients: a comprehensive review

@en

Association of cetuximab with ...... tients: a comprehensive review

@en-gb

Association of cetuximab with ...... tients: a comprehensive review

@nl

prefLabel

Association of cetuximab with ...... tients: a comprehensive review

@ast

Association of cetuximab with ...... tients: a comprehensive review

@en

Association of cetuximab with ...... tients: a comprehensive review

@en-gb

Association of cetuximab with ...... tients: a comprehensive review

@nl

P1433

Q21198850-327E8769-F194-4772-9009-6AC57FAACD69

P1476

Q21198850-E55B1F33-100A-42C4-8918-DD51598A600C

P2093

Q21198850-08DFACD1-9A2B-4B0E-A6DE-CCE9F4648BB4

Q21198850-12502AEB-6F2C-4D7C-BDF9-81BE6A586770

Q21198850-648BE1EA-AF07-4F9E-9FB4-7B65AAEF9F3C

Q21198850-CF84C36E-5E97-434D-8488-7408CF779BC8

Q21198850-D15A844C-E04E-41C3-A707-CD5A2EF106C6

Q21198850-DDDB2D1B-C3C4-4B79-AC03-2A2A9E34AA7C

P275

Q21198850-04C9AC7A-874D-4B0D-9EC9-BE46FBC43A4D

P2860

Q21198850-034C6F58-57EF-4297-9C30-FA1249BAA384

Q21198850-050C80DA-3817-4F1F-8036-B17EDD11AB7D

Q21198850-0925A629-71D0-46B2-8714-84E1196B78FB

Q21198850-0AA2DDC9-70A5-4B57-B12C-CD25D3AE08B7

Q21198850-0E016EC0-7EB3-43C1-9746-31E2DD5F7386

Q21198850-0F33795F-56D3-40DD-8BC0-E34FAED16A0E

Q21198850-2A43A526-20BB-4DE4-A9C1-BA8CF1B75251

Q21198850-2ABD5CCC-0D30-4BC8-B937-EF500E4D869A

Q21198850-2EEA03BC-12F2-4CF5-888E-3EC617CCF875

Q21198850-3B897976-4F5B-4C09-A05C-6E9788916540

P2888

Q21198850-A7FA6460-3C28-4918-848D-3EE39A6B28D8

P304

Q21198850-C481B6CC-94E2-44BB-AD08-FB086F812B62

P31

Q21198850-2D12AA42-1DE2-4E47-8847-AEF5873A86CE

Q21198850-37FC8886-85D1-4134-A5EB-0012D9C96CF5

P3181

Q21198850-D38A7BF7-D8E1-492D-99DC-B457151392DF

P356

Q21198850-556C1825-4EDD-412E-8D99-0FBAC8E7E149

P407

Q21198850-98D38A9C-E2BC-4107-AD3A-64AE4A9ECD75

P433

Q21198850-4551905C-6135-4573-A677-AC63F8222904

P478

Q21198850-35FF2E61-ACC4-4C1F-A18B-E3F8A6A05A94

P5008

Q21198850-44C5CF9E-2E2C-4149-8C42-A4F773B2EAC1

P577

Q21198850-D22212EB-3B78-481E-B66B-37D70067381B

P5875

Q21198850-61384295-CA1C-4981-80A4-3A601F813354

P6179

Q21198850-1C509DEE-6411-4A7E-9BF1-C620439C1EDC

P698

Q21198850-F38EE2ED-1FE9-4BD0-BC5A-854F8F032C6A

P921

Q21198850-1397D7D6-A480-465C-980E-DFFF272C4122

Q21198850-43506F82-90E5-43DF-93AE-BE565311860F

Q21198850-6931083B-C17E-4C69-8951-088F272D0856

Q21198850-70547DDB-AE5E-4435-9939-8B061C5D3CEB

Q21198850-73A3BA95-135F-4EE1-9773-E87FE1CBC304

Q21198850-9274E422-4B5C-4C77-8B76-4742EF6F8EC1

P932

Q21198850-F7AECC73-95CF-4133-BE1F-6875CD2F81BB

P3181

P356

1756-9966-28-113

P1433

Journal of Experimental & Clinical Cancer Research

P1476

Association of cetuximab with ...... tients: a comprehensive review

@en

P2093

Aimel Azizi

http://www.w3.org/2001/XMLSchema#string

Jason Lu

http://www.w3.org/2001/XMLSchema#string

Jeffrey B Hoag

http://www.w3.org/2001/XMLSchema#string

Mark E Lund

http://www.w3.org/2001/XMLSchema#string

Rudolph E Willis

http://www.w3.org/2001/XMLSchema#string

Timothy J Doherty

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.0 Generic

P2860

ErbB receptors: from oncogenes to targeted cancer therapies

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

Cetuximab for the treatment of colorectal cancer.

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

Cetuximab-associated infusion reactions: pathology and management.

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.

Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study.

Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study.

P2888

1756-9966-28-113

P304

113

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3519642

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/1756-9966-28-113

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2009-08-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26743577

http://www.w3.org/2001/XMLSchema#string

P6179

1024821101

http://www.w3.org/2001/XMLSchema#string

P698

19682368

http://www.w3.org/2001/XMLSchema#string

P921

monoclonal antibody

Anagraw amesgunef

P932

2735734

http://www.w3.org/2001/XMLSchema#string